Shire’s NPS Purchase Highlights Its Orphan Drug Strategy Post-AbbVie Bid
The Dublin-based drugmaker’s buy of rare disease specialist NPS Pharma signals it is back on the offensive after AbbVie’s aborted bid, but observers say the deal’s sound logic may make Shire a takeover target again.
You may also be interested in...
Arena's Phase IIb CAPTIVATE trial assessing investigational olorinab in IBS missed its primary endpoint.
The independent, family-controlled German group has signed a third R&D pact with Danish biotech Gubra to develop poly-agonist peptides for obesity.
Germany’s Merck has licensed exclusive rights to develop and sell Debiopharm’s potential first-in-class inhibitor of apoptosis proteins (IAP) antagonist, targeting head and neck cancers.